Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Prolia clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 8 trials in our China, Denmark, Turkey, Canada and Australia registers that name Prolia as an intervention. Synced 10 Nov 2026
8Current trials
2Recruiting now
7Lead sponsors
5Country registers
At a glance

Prolia is named as an intervention in 8 current clinical trials in our China, Denmark, Turkey, Canada and Australia registers. 2 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Amgen (2). The most-studied condition is Osteoporosis.

Patient leaflets for Prolia

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting225%
  • Not yet open225%
  • Active, closed450%

Trials by phase

  • Phase 4450%
  • Phase 3225%
  • Phase 2225%
01

Clinical trials of Prolia

8 trials
StudyPhaseStatusLead sponsorRegisters
A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®
NCT07062978 · ClinicalTrials.gov ↗ · Postmenopausal Women With Osteoporosis at High Risk of Fracture
Phase 3 Recruiting Qilu Pharmaceutical Co., Ltd China
Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults
NCT04608630 · ClinicalTrials.gov ↗ · Critical Illness, Osteoporosis
Phase 2 Recruiting Australian and New Zealand Intensive Care Research Centre Australia
Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures
NCT06720350 · ClinicalTrials.gov ↗ · Osteoporosis in Post-menopausal Women
Phase 4 Not yet open Marmara University Turkey
RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients
NCT07056478 · ClinicalTrials.gov ↗ · Sarcopenia in Elderly
Phase 3 Not yet open Prince of Wales Hospital, Shatin, Hong Kong China
PRevEnting FracturEs in REnal Disease - 1
NCT05096195 · ClinicalTrials.gov ↗ · Kidney Diseases, Dialysis; Complications, Fragility Fracture
Phase 4 Active, closed Western University, Canada Canada
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
NCT06332014 · Osteoporosis
Phase 4 Active, closed Amgen China
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
NCT06588153 · Glucocorticoid-induced Osteoporosis
Phase 4 Active, closed Amgen China
FITMI - First In Treating Male Infertility
NCT05212337 · ClinicalTrials.gov ↗ · Infertility, Male
Phase 2 Active, closed Martin Blomberg Jensen Denmark

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Prolia

11 conditions
Osteoporosis2Glucocorticoid-induced Osteoporosis1Postmenopausal Women With Osteoporosis at High Risk of Fracture1Sarcopenia in Elderly1Infertility, Male1Osteoporosis in Post-menopausal Women1Kidney Diseases1Dialysis; Complications1Fragility Fracture1Chronic Kidney Disease-Mineral and Bone Disorder1Critical Illness1
05

Related compounds

06

Questions about Prolia trials

How many clinical trials are testing Prolia?

8 current trials in our China, Denmark, Turkey, Canada and Australia registers name Prolia as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Prolia trials recruiting patients?

Yes. 2 of the 8 trials are recruiting: 1 with sites in China and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Prolia clinical trials?

Amgen (2), Qilu Pharmaceutical Co., Ltd (1), Prince of Wales Hospital, Shatin, Hong Kong (1) and Martin Blomberg Jensen (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Prolia works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Prolia works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Prolia (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.